Advertisement

Topics

Domain Therapeutics launches Mavalon with €9mm Series A round from Medicxi

15:40 EDT 18 Oct 2016 | Elsevier Business Intelligence

VC firm Medicxi invested €9mm ($9.9mm) to launch a new UK pharmaceutical company, Mavalon Therapeutics Ltd., formed to advance Domain Therapeutics SA's small-molecule G protein-coupled receptor (GPCR) pipeline in the area of Parkinson's disease.

Original Article: Domain Therapeutics launches Mavalon with €9mm Series A round from Medicxi

NEXT ARTICLE

More From BioPortfolio on "Domain Therapeutics launches Mavalon with €9mm Series A round from Medicxi"

Quick Search
Advertisement
 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...


Searches Linking to this Story